These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
84 related articles for article (PubMed ID: 12001423)
1. [Usefulness of scintigraphy images with 111In-CYT-103 in the diagnosis of colonic and rectal recurrence]. García-Fernández R; Luna-Pérez P; Hernández-Hernández DM; Iwasaki-Otake L; Pichardo-Romero P; Rodríguez-Ramirez S Gac Med Mex; 2002; 138(2):139-44. PubMed ID: 12001423 [TBL] [Abstract][Full Text] [Related]
2. 111In-CYT-103 scanning in recurrent colorectal cancer--does it affect standard management? Dominguez JM; Wolff BG; Nelson H; Forstrom LA; Mullan BP Dis Colon Rectum; 1996 May; 39(5):514-9. PubMed ID: 8620800 [TBL] [Abstract][Full Text] [Related]
8. [Indium 111-labeled antibodies in the detection of colorectal carcinoma]. Artiko V; Obradović V; Davidović B; Petrović N; Petrović M; Krivokapić Z; Pavlov M; Adanja G; Sobić D; Vlajković M; Pavlović S; Rebić R Acta Chir Iugosl; 2003; 50(4):43-6. PubMed ID: 15307496 [TBL] [Abstract][Full Text] [Related]
9. Detection of recurrent colorectal carcinoma with In-111 CYT-103 scintigraphy in a patient with nondiagnostic MRI and CT. Edlin JP; Kahn D Clin Nucl Med; 1994 Nov; 19(11):1004-7. PubMed ID: 7842571 [TBL] [Abstract][Full Text] [Related]
10. Radioimmunoguided surgery of colorectal carcinoma with an 111In-labelled anti-TAG72 monoclonal antibody. Muxi A; Pons F; Vidal-Sicart S; Setoain FJ; Herranz R; Novell F; Fernandez RM; Trias M; Setoain J Nucl Med Commun; 1999 Feb; 20(2):123-30. PubMed ID: 10088160 [TBL] [Abstract][Full Text] [Related]
11. Clinical experience with radiolabelled monoclonal antibodies in the detection of colorectal and ovarian carcinoma recurrence and review of the literature. Pinkas L; Robins PD; Forstrom LA; Mahoney DW; Mullan BP Nucl Med Commun; 1999 Aug; 20(8):689-96. PubMed ID: 10451876 [TBL] [Abstract][Full Text] [Related]
12. Comparison of iodine-123-vasoactive intestinal peptide receptor scintigraphy and indium-111-CYT-103 immunoscintigraphy. Raderer M; Becherer A; Kurtaran A; Angelberger P; Li S; Leimer M; Weinlaender G; Kornek G; Kletter K; Scheithauer W; Virgolini I J Nucl Med; 1996 Sep; 37(9):1480-7. PubMed ID: 8790198 [TBL] [Abstract][Full Text] [Related]
13. Immunoscintigraphy performed with In-111-labeled CYT-103 in the management of colorectal cancer: comparison with CT. Collier BD; Abdel-Nabi H; Doerr RJ; Harwood SJ; Olsen J; Kaplan EH; Winzelberg GG; Grossman SJ; Krag DN; Mitchell EP Radiology; 1992 Oct; 185(1):179-86. PubMed ID: 1523304 [TBL] [Abstract][Full Text] [Related]
14. Multicenter clinical trial of 111In-CYT-103 in patients with ovarian cancer. Gallup DG Targeted Diagn Ther; 1992; 6():111-24. PubMed ID: 1576342 [No Abstract] [Full Text] [Related]
15. Role of In-111 labeled CYT-103 immunoscintigraphy in the evaluation of patients with recurrent colorectal carcinoma. Markowitz A; Saleemi K; Freeman LM Clin Nucl Med; 1993 Aug; 18(8):685-700. PubMed ID: 8403703 [TBL] [Abstract][Full Text] [Related]
16. Use of OncoScint scan to assess resectability of hepatic metastases from colorectal cancer. Su WT; Brachman M; O'Connell TX Am Surg; 2001 Dec; 67(12):1200-3. PubMed ID: 11768830 [TBL] [Abstract][Full Text] [Related]